Biofrontera Inc.(BFRI)

Medical - Pharmaceuticals · Woburn, MA

$0.86-0.03 (-3.19%)

Delayed quote: Oct 6, 2026, 10:39 AM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:41:02.720Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:41:02.720Z.

Quote observation: 2026-10-06T14:39:37.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 11,042,884
Total debt · period ending 2026-06-30: 7,504,000
Cash · period ending 2026-06-30: 4,659,000
TTM operating income · period ending 2026-06-30: -4,364,000

FMP input reference: b47096c20191003074eea3dc75a1498d2bed5743fa2797f84e024bc92f81a74c

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

BFRI EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

BFRI Competitors' EV/EBIT Ratio

BFRI

Biofrontera Inc.

Current

Market Cap

$11.04M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BIVI

BioVie Inc.

vs BFRI

Market Cap

$11.01M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNSY

Cerenome, Inc.

vs BFRI

Market Cap

$10.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPRX

Kiora Pharmaceuticals, Inc.

vs BFRI

Market Cap

$11.30M

EV/EBIT Ratio

N/A

TTM Avg

13.02x

3Y Avg

13.02x

5Y Avg

13.02x

GDTC

CytoMed Therapeutics Limited

vs BFRI

Market Cap

$10.75M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LSTA

Lisata Therapeutics, Inc.

vs BFRI

Market Cap

$11.38M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADIL

Adial Pharmaceuticals, Inc.

vs BFRI

Market Cap

$11.42M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MSLE

Satellos Bioscience Inc.

vs BFRI

Market Cap

$10.52M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BFRG

Bullfrog AI Holdings, Inc. Common Stock

vs BFRI

Market Cap

$11.67M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LTRN

Lantern Pharma Inc.

vs BFRI

Market Cap

$11.81M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Biofrontera Inc. (BFRI)	$11.04M	N/A	N/A	N/A	N/A
BioVie Inc. (BIVI)vs ›	$11.01M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$10.81M	N/A	N/A	N/A	N/A
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.30M	N/A	13.02x	13.02x	13.02x
CytoMed Therapeutics Limited (GDTC)vs ›	$10.75M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$11.38M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$11.42M	N/A	N/A	N/A	N/A
Satellos Bioscience Inc. (MSLE)vs ›	$10.52M	N/A	N/A	N/A	N/A
Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs ›	$11.67M	N/A	N/A	N/A	N/A
Lantern Pharma Inc. (LTRN)vs ›	$11.81M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

BFRI EV/EBIT Ratio Metrics

BFRI Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics